Related references
Note: Only part of the references are listed.Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy
Yaling Guo et al.
RENAL FAILURE (2020)
Insights into the Role of Renal Biopsy in Patients with T2DM: A Literature Review of Global Renal Biopsy Results
Xue Tong et al.
DIABETES THERAPY (2020)
ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE
Adrian Liew et al.
NEPHROLOGY (2020)
Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Juergen Floege et al.
KIDNEY INTERNATIONAL (2019)
Efficacy and safety of leflunomide in IgA nephropathy: a systematic review and meta-analysis
Jianwei Yi et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2019)
Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial
Minfang Zhang et al.
CLINICAL RHEUMATOLOGY (2019)
Leflunomide: A promising drug with good antitumor potential
Chunying Zhang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Advanced glycation end products in the pathogenesis of chronic kidney disease
Naila Rabbani et al.
KIDNEY INTERNATIONAL (2018)
Optineurin-mediated mitophagy protects renal tubular epithelial cells against accelerated senescence in diabetic nephropathy
Kehong Chen et al.
CELL DEATH & DISEASE (2018)
Changes in the Spectrum of Kidney Diseases: An Analysis of 40,759 Biopsy-Proven Cases from 2003 to 2014 in China
Jin-Hua Hou et al.
KIDNEY DISEASES (2018)
Idiopathic membranous nephropathy in patients with diabetes mellitus: a diagnostic and therapeutic quandary
Dharmendra Bhadauria et al.
CLINICAL KIDNEY JOURNAL (2018)
The role of the complement system in diabetic nephropathy
Allan Flyvbjerg
NATURE REVIEWS NEPHROLOGY (2017)
Cellular senescence, senescence-associated secretory phenotype, and chronic kidney disease
Wen-Juan Wang et al.
ONCOTARGET (2017)
Membranous nephropathy occurring with type 2 diabetes mellitus
Yujun Qian et al.
CLINICAL NEPHROLOGY (2017)
Protective effects of leflunomide on renal lesions in a rat model if diabetic nephropathy
Qing Zhang et al.
RENAL FAILURE (2016)
Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating Sirt1 to resist AGEs-induced upregulation of fibronetin and transforming growth factor-β1 in rat glomerular messangial cells
Kaipeng Huang et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2015)
Non-diabetic renal disease with or without diabetic nephropathy in type 2 diabetes: clinical predictors and outcome
Tayebeh Soleymanian et al.
RENAL FAILURE (2015)
Leflunomide in idiopathic membranous nephropathy: A new immunosuppressive with promising treatment potential
Chien-Liang Chen et al.
NEPHROLOGY (2014)
Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: A retrospective clinical study of efficacy and safety
Shifeng Yang et al.
NEPHROLOGY (2013)
Experimental study of leflunomide on renal protective effect and on inflammatory response of streptozotocin induced diabetic rats
Wei-Min Yu et al.
NEPHROLOGY (2012)
Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy
P Hovind et al.
KIDNEY INTERNATIONAL (2004)
Share Paper
